Chinese Biological Omicorn inactivated Vaccine obtained Clinical approval from Drug Administration
On April 26th, novel coronavirus inactivated vaccine of Omicron mutant of Sinopharmaceutical Group China Biology Beijing Biological products Research Institute was approved by the State Drug Administration for the first time in China.
After the news was announced, the shares of Sinopharmaceuticals rose in a straight line by the daily limit, while those of Sinopharmaceuticals and Hyundai rose.
$China National Medicines Corporation(600511.SH$
After the news was announced, the shares of Sinopharmaceuticals rose in a straight line by the daily limit, while those of Sinopharmaceuticals and Hyundai rose.
$China National Medicines Corporation(600511.SH$
According to the announcement, Chinese biology will conduct a sequential immune clinical study in the form of a randomized, double-blind, cohort study in people aged 18 and over who have completed two or three doses of COVID-19 vaccine. to evaluate the safety and immunogenicity of the inactivated vaccine against Omicron mutant novel coronavirus.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Twitter@Sino_Market | Realtime Chinese market info provider.
9229Followers
4Following
8777Visitors
Follow